Clinical Research Drugs Treatment White Paper 
Conversations in Drug Development Trends
MARCH 20, 2024
In the increasingly advancing world of medicine, personalized care is a key factor that can progress your drug development efforts. One way to ensure customized disease management is to utilize pharmacogenomics (PGx) in your clinical trial. Certain variants of CPY2D6 reduce enzyme activity, thereby reducing the benefit of Tamoxifen.
PPD
OCTOBER 12, 2023
These treatments use a vector to introduce the desired nucleic acid code to replace or modify protein expression or use cells to alter/restore a specific cell type. There are over 2,000 CGTs currently being evaluated in clinical trials, with more than 200 in Phase III and 10-20 per year estimated to come to market by 2025.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
PPD
MARCH 21, 2024
When participating in clinical trials, pediatric populations require distinct considerations for their safety and well-being — which can present unique challenges for drug developers. A number of strategies can be adopted to put the needs of the child at the center of the study.
The Pharma Data
SEPTEMBER 11, 2020
In an effort to slow the spread of the disease and prevent a second wave, pharma companies around the world are continuously looking to advance new methods of treatment. Starpharma experimenting with Gilead’s antiviral drug for easier administration. acting, water-soluble version of remdesivir. Saama Technologies, Inc. ,
The Pharma Data
OCTOBER 16, 2020
With many nationwide and regional lockdowns coming into force, virtual clinical trials are proving to be an effective way to monitor patients remotely. BetterLife conducts patient centric study via a fully remote clinical trial. All of these technologies can be used on a variety of devices.
Conversations in Drug Development Trends
JULY 29, 2024
Despite these advancements, challenges for widespread effective care remain due to the heterogeneous patient population, opening the door for further development of treatments for T2D. Obesity is a major factor in the prevalence of T2D, and it is vital to develop T2D treatments with this in mind.
Conversations in Drug Development Trends
MARCH 1, 2024
To help determine if a master protocol could be a good fit for your study, check out this white paper for a more comprehensive overview of the appropriateness of master protocols in different contexts. Here are some relevant factors below: What Are the Advantages of a Master Protocol? Contact us.
Expert insights. Personalized for you.
52 
Let's personalize your content